Macquarie Group LTD Rigel Pharmaceuticals Inc Transaction History

Macquarie Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.1 - $12.2 $3,577 - $39,674	-3,252 Reduced 0.2%	1,600,000 $1.89 Million
Q1 2021 May 14, 2021	SELL	$3.35 - $4.93 $5,165 - $7,602	-1,542 Reduced 0.1%	1,603,252 $5.48 Million
Q2 2020 Aug 11, 2020	BUY	$1.41 - $2.05 $6,759 - $9,827	4,794 Added 0.3%	1,604,794 $2.94 Million
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $1.98 Million - $2.88 Million	700,000 Added 77.78%	1,600,000 $4.53 Million
Q1 2018 May 11, 2018	BUY	$3.54 - $4.54 $410,328 - $526,240	115,912 Added 14.78%	900,000 $3.19 Million
Q4 2017 Feb 15, 2018	BUY	$3.23 - $4.3 $161,500 - $215,000	50,000 Added 6.81%	784,088 $3.04 Million
Q3 2017 Nov 08, 2017	BUY	$2.18 - $2.57 $1.6 Million - $1.89 Million	734,088	734,088 $1.87 Million

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.